Base de dados : MEDLINE
Pesquisa : G03.787 [Categoria DeCS]
Referências encontradas : 8052 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 806 ir para página                         

  1 / 8052 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29431542
[Au] Autor:Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
[Ad] Endereço:a Department of Clinical Pharmacy , St. Antonius Hospital , Nieuwegein , The Netherlands.
[Ti] Título:Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
[So] Source:Expert Opin Drug Metab Toxicol;14(3):275-285, 2018 Mar.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The rising prevalence of obesity confronts clinicians with dosing problems in the (extreme) overweight population. Obesity has a great impact on key organs that play a role in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, however the ultimate impact of these changes on how to adapt the dose may not always be known. Areas covered: In this review, physiological changes associated with obesity are discussed. An overview is provided on the alterations in absorption, distribution, drug metabolism and clearance in (morbid) obesity focusing on general principles that can be extracted from pharmacokinetic studies. Also, relevant pharmacodynamic considerations in obesity are discussed. Expert opinion: Over the last two decades, increased knowledge is generated on PK and PD in obesity. Future research should focus on filling in the knowledge gaps that remain, especially in connecting obesity-related physiological changes with changes in PK and/or PD and vice versa. Ultimately, this knowledge can be used to develop physiologically based PK and PD models on the basis of quantitative systems pharmacology principles. Moreover, efforts should focus on thorough prospective evaluation of developed model-based doses with subsequent implementation of these dosing recommendations in clinical practice.
[Mh] Termos MeSH primário: Obesidade Mórbida/metabolismo
Obesidade/metabolismo
Preparações Farmacêuticas/metabolismo
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Seres Humanos
Modelos Biológicos
Preparações Farmacêuticas/administração & dosagem
Farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pharmaceutical Preparations)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1440287


  2 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29377912
[Au] Autor:Robertson MJ; Soibam B; O'Leary JG; Sampaio LC; Taylor DA
[Ad] Endereço:Scientific Stem Cell, Texas Heart Institute, Houston, Texas, United States of America.
[Ti] Título:Recellularization of rat liver: An in vitro model for assessing human drug metabolism and liver biology.
[So] Source:PLoS One;13(1):e0191892, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liver-like organoids that recapitulate the complex functions of the whole liver by combining cells, scaffolds, and mechanical or chemical cues are becoming important models for studying liver biology and drug metabolism. The advantages of growing cells in three-dimensional constructs include enhanced cell-cell and cell-extracellular matrix interactions and preserved cellular phenotype including, prevention of de-differentiation. In the current study, biomimetic liver constructs were made via perfusion decellularization of rat liver, with the goal of maintaining the native composition and structure of the extracellular matrix. We optimized our decellularization process to produce liver scaffolds in which immunogenic residual DNA was removed but glycosaminoglycans were maintained. When the constructs were recellularized with rat or human liver cells, the cells remained viable, capable of proliferation, and functional for 28 days. Specifically, the cells continued to express cytochrome P450 genes and maintained their ability to metabolize a model drug, midazolam. Microarray analysis showed an upregulation of genes involved in liver regeneration and fibrosis. In conclusion, these liver constructs have the potential to be used as test beds for studying liver biology and drug metabolism.
[Mh] Termos MeSH primário: Fígado/citologia
Modelos Animais
Farmacocinética
[Mh] Termos MeSH secundário: Animais
Reatores Biológicos
Adesão Celular
Proliferação Celular
Meios de Cultura
Matriz Extracelular
Hepatócitos/efeitos dos fármacos
Hepatócitos/metabolismo
Seres Humanos
Técnicas In Vitro
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Culture Media)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191892


  3 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29373599
[Au] Autor:Lim S; Lee K; Kang J
[Ad] Endereço:Department of Computer Science and Engineering, Korea University, Seoul, Korea.
[Ti] Título:Drug drug interaction extraction from the literature using a recursive neural network.
[So] Source:PLoS One;13(1):e0190926, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Detecting drug-drug interactions (DDI) is important because information on DDIs can help prevent adverse effects from drug combinations. Since there are many new DDI-related papers published in the biomedical domain, manually extracting DDI information from the literature is a laborious task. However, text mining can be used to find DDIs in the biomedical literature. Among the recently developed neural networks, we use a Recursive Neural Network to improve the performance of DDI extraction. Our recursive neural network model uses a position feature, a subtree containment feature, and an ensemble method to improve the performance of DDI extraction. Compared with the state-of-the-art models, the DDI detection and type classifiers of our model performed 4.4% and 2.8% better, respectively, on the DDIExtraction Challenge'13 test data. We also validated our model on the PK DDI corpus that consists of two types of DDIs data: in vivo DDI and in vitro DDI. Compared with the existing model, our detection classifier performed 2.3% and 6.7% better on in vivo and in vitro data respectively. The results of our validation demonstrate that our model can automatically extract DDIs better than existing models.
[Mh] Termos MeSH primário: Mineração de Dados/métodos
Interações Medicamentosas
Redes Neurais (Computação)
[Mh] Termos MeSH secundário: Mineração de Dados/estatística & dados numéricos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Seres Humanos
Processamento de Linguagem Natural
Farmacocinética
Publicações
Máquina de Vetores de Suporte
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190926


  4 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28988506
[Au] Autor:Alqahtani S
[Ad] Endereço:a Department of Clinical Pharmacy, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
[Ti] Título:In silico ADME-Tox modeling: progress and prospects.
[So] Source:Expert Opin Drug Metab Toxicol;13(11):1147-1158, 2017 Nov.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Although significant progress has been made in high-throughput screening of absorption, distribution, metabolism and excretion, and toxicity (ADME-Tox) properties in drug discovery and development, in silico ADME-Tox prediction continues to play an important role in facilitating the appropriate selection of candidate drugs by pharmaceutical companies prior to expensive clinical trials. Areas covered: This review provides an overview of the available in silico models that have been used to predict the ADME-Tox properties of compounds. It also provides a comprehensive overview and summarization of the latest modeling methods and algorithms available for the prediction of physicochemical characteristics, ADME properties, and drug toxicity issues. Expert opinion: The in silico models currently available have greatly contributed to the knowledge of screening approaches in the early stages of drug discovery and the development process. As the definitive goal of in silico molding is to predict the pharmacokinetics and disposition of compounds in vivo by assembling all kinetic processes within one global model, PBPK models can serve this purpose. However, much work remains to be done in this area to generate more data and input parameters to build more reliable and accurate prediction models.
[Mh] Termos MeSH primário: Desenho de Drogas
Modelos Biológicos
Farmacocinética
[Mh] Termos MeSH secundário: Algoritmos
Animais
Simulação por Computador
Descoberta de Drogas/métodos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle
Ensaios de Triagem em Larga Escala
Seres Humanos
Preparações Farmacêuticas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pharmaceutical Preparations)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2017.1389897


  5 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28968417
[Au] Autor:de Vries EM; Oosterman JE; Eggink HM; de Goede P; Sen S; Foppen E; Boudzovitch-Surovtseva O; Boelen A; Romijn JA; laFleur SE; Kalsbeek A
[Ad] Endereço:Department of Medicine, Academic Medical Center, Amsterdam, the Netherlands.
[Ti] Título:Effects of meal composition and meal timing on the expression of genes involved in hepatic drug metabolism in rats.
[So] Source:PLoS One;12(10):e0185520, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: With chronotherapy, drug administration is synchronized with daily rhythms in drug clearance and pharmacokinetics. Daily rhythms in gene expression are centrally mastered by the suprachiasmatic nucleus of the hypothalamus as well as by tissue clocks containing similar molecular mechanisms in peripheral organs. The central timing system is sensitive to changes in the external environment such as those of the light-dark cycle, meal timing and meal composition. We investigated how changes in diet composition and meal timing would affect the daily hepatic expression rhythms of the nuclear receptors PXR and CAR and of enzymes involved in P450 mediated drug metabolism, as such changes could have consequences for the practice of chronotherapy. MATERIALS AND METHODS: Rats were subjected to either a regular chow or a free choice high-fat-high-sugar (fcHFHS) diet. These diets were provided ad libitum, or restricted to either the light phase or the dark phase. In a second experiment, rats had access to chow either ad libitum or in 6 meals equally distributed over 24 hours. RESULTS: Pxr, Alas1 and Por displayed significant day-night rhythms under ad libitum chow fed conditions, which for Pxr was disrupted under fcHFHS diet conditions. Although no daily rhythms were detected in expression of CAR, Cyp2b2 and Cyp3a2, the fcHFHS diet did affect basal expression of these genes. In chow fed rats, dark phase feeding induced a diurnal rhythm in Cyp2b2 expression while light phase feeding induced a diurnal rhythm in Car expression and completely shifted the peak expression of Pxr, Car, Cyp2b2, Alas1 and Por. The 6-meals-a-day feeding only abolished the Pxr rhythm but not the rhythms of the other genes. CONCLUSION: We conclude that although nuclear receptors and enzymes involved in the regulation of hepatic drug metabolism are sensitive to meal composition, changes in meal timing are mainly effectuated via changes in the molecular clock.
[Mh] Termos MeSH primário: Comportamento Alimentar
Expressão Gênica
Fígado/metabolismo
Preparações Farmacêuticas/metabolismo
[Mh] Termos MeSH secundário: Ração Animal
Animais
Cronoterapia
Ritmo Circadiano
Sistema Enzimático do Citocromo P-450/metabolismo
Masculino
Farmacocinética
Ratos
Ratos Wistar
Reação em Cadeia da Polimerase em Tempo Real
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pharmaceutical Preparations); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185520


  6 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28885074
[Au] Autor:Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
[Ad] Endereço:a Department of Traditional Pharmacy, School of Traditional Medicine , Tehran University of Medical Sciences , Tehran , Iran.
[Ti] Título:Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
[So] Source:Expert Opin Drug Metab Toxicol;13(10):1047-1062, 2017 Oct.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: St. John's wort (SJW) is a common medicinal herb used for the treatment of mild to moderate depression. Hyperforin, one of the chief components of SJW, plays an important role in the induction of cytochrome P450 enzymes (CYP) and P-glycoprotein transporter (P-gp), and therefore, affects the pharmacokinetics of various drugs. There are several clinical studies demonstrating the interaction of SJW with the metabolism of conventional drugs which may cause life-threatening events. Areas covered: This review focuses on human studies that have evaluated pharmacokinetic alterations of conventional drugs in concomitant use with different SJW preparations. Expert opinion: SJW preparations have demonstrated clinically important interactions with several classes of conventional drugs such as immunosuppressants, anticancer agents, cardiovascular drugs, oral contraceptives, and lipid lowering agents that caused life-threatening events in several cases. The patient information label on the SJW products should provide enough information regarding the possible risk of interaction. Hyperforin seems to be the major ingredient responsible for CYP and P-gp inducing activity of SJW; thus, hyperforin-free products may be future candidates to decrease SJW's drug interactions.
[Mh] Termos MeSH primário: Interações Ervas-Drogas
Hypericum/química
Preparações de Plantas/administração & dosagem
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo
Animais
Sistema Enzimático do Citocromo P-450/efeitos dos fármacos
Depressão/tratamento farmacológico
Seres Humanos
Farmacocinética
Floroglucinol/análogos & derivados
Floroglucinol/isolamento & purificação
Floroglucinol/farmacologia
Preparações de Plantas/efeitos adversos
Preparações de Plantas/farmacologia
Terpenos/isolamento & purificação
Terpenos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Plant Preparations); 0 (Terpenes); 9035-51-2 (Cytochrome P-450 Enzyme System); DHD7FFG6YS (Phloroglucinol); RM741E34FP (hyperforin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2017.1378342


  7 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28846728
[Au] Autor:Alidori S; Thorek DLJ; Beattie BJ; Ulmert D; Almeida BA; Monette S; Scheinberg DA; McDevitt MR
[Ad] Endereço:Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
[Ti] Título:Carbon nanotubes exhibit fibrillar pharmacology in primates.
[So] Source:PLoS One;12(8):e0183902, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nanomedicine rests at the nexus of medicine, bioengineering, and biology with great potential for improving health through innovation and development of new drugs and devices. Carbon nanotubes are an example of a fibrillar nanomaterial poised to translate into medical practice. The leading candidate material in this class is ammonium-functionalized carbon nanotubes (fCNT) that exhibits unexpected pharmacological behavior in vivo with important biotechnology applications. Here, we provide a multi-organ evaluation of the distribution, uptake and processing of fCNT in nonhuman primates using quantitative whole body positron emission tomography (PET), compartmental modeling of pharmacokinetic data, serum biomarkers and ex vivo pathology investigation. Kidney and liver are the two major organ systems that accumulate and excrete [86Y]fCNT in nonhuman primates and accumulation is cell specific as described by compartmental modeling analyses of the quantitative PET data. A serial two-compartment model explains renal processing of tracer-labeled fCNT; hepatic data fits a parallel two-compartment model. These modeling data also reveal significant elimination of the injected activity (>99.8%) from the primate within 3 days (t1/2 = 11.9 hours). These favorable results in nonhuman primates provide important insight to the fate of fCNT in vivo and pave the way to further engineering design considerations for sophisticated nanomedicines to aid late stage development and clinical use in man.
[Mh] Termos MeSH primário: Nanotubos de Carbono
[Mh] Termos MeSH secundário: Animais
Materiais Biocompatíveis
Biomarcadores/sangue
Rim/efeitos dos fármacos
Fígado/efeitos dos fármacos
Camundongos
Camundongos Endogâmicos BALB C
Nanotubos de Carbono/toxicidade
Farmacocinética
Tomografia por Emissão de Pósitrons
Primatas
Distribuição Tecidual
Radioisótopos de Ítrio/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Biomarkers); 0 (Nanotubes, Carbon); 0 (Yttrium Radioisotopes)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183902


  8 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28821193
[Au] Autor:Cheng CW; Hendrickson JE; Tormey CA; Sidhu D
[Ad] Endereço:Departments of Laboratory Medicine.
[Ti] Título:Therapeutic Plasma Exchange and Its Impact on Drug Levels: An ACLPS Critical Review.
[So] Source:Am J Clin Pathol;148(3):190-198, 2017 Sep 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: To examine and summarize the current literature on the effects of therapeutic plasma exchange on medication levels. Methods: Literature review was performed via searches of the Cochrane Database and PubMed-MEDLINE (1996 to August 2016) looking for all case reports, case series, and human randomized controlled trials involving therapeutic plasma exchange (TPE)-associated drug removal. Results: Approximately 60 peer-reviewed articles were identified with the majority being case reports; no randomized controlled trials were identified. These reports and the authors' own experiences were used to derive practical guidance regarding the effect of TPE on circulating drug levels. Conclusions: There were several limitations with existing studies, many of which relate to procedural and/or clinical properties of patients undergoing TPE. As such, additional studies are needed before definitive guidelines can be established. There is clear need for development of consensus and additional investigations in this domain.
[Mh] Termos MeSH primário: Troca Plasmática/efeitos adversos
[Mh] Termos MeSH secundário: Seres Humanos
Farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170820
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx056


  9 / 8052 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28820269
[Au] Autor:Di L
[Ad] Endereço:a Pharmacokinetics, Dynamics and Metabolism , Pfizer Inc , Groton , CT , USA.
[Ti] Título:Reaction phenotyping to assess victim drug-drug interaction risks.
[So] Source:Expert Opin Drug Discov;12(11):1105-1115, 2017 Nov.
[Is] ISSN:1746-045X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Reaction phenotyping provides critical information regarding the fraction metabolized (f ) of drug candidates. It has become increasingly important in drug discovery and development as it can be used to assess victim drug-drug interaction potential, guide structural modification to reduce f , inform clinical study design, predict individual variability in pharmacokinetics, and evaluate the impact of genetic polymorphisms. Areas covered: The currently available in vitro and in vivo methods for reaction phenotyping are summarized along with their advantages, limitations and timings for application during the different stages of drug discovery and development. Challenges of reaction phenotyping for low clearance compounds, non-Cytochrome P450 (CYP) enzymes, extrahepatic contribution and atypical kinetics are highlighted and various approaches are discussed. Expert opinion: Certain areas of reaction phenotyping remain challenging with the current state of the science. In order to better define f in this challenging space, there needs to be future advances in selective inhibitors and specific substrate reactions for non-CYP enzymes, availability of high quality and low cost recombinant enzymes, tissue distribution and in vitro-in vivo correlation, scaling factors for extrahepatic enzymes and the next generation of low clearance tools.
[Mh] Termos MeSH primário: Desenho de Drogas
Descoberta de Drogas/métodos
Interações Medicamentosas
[Mh] Termos MeSH secundário: Animais
Sistema Enzimático do Citocromo P-450/metabolismo
Enzimas/metabolismo
Seres Humanos
Preparações Farmacêuticas/metabolismo
Farmacocinética
Fenótipo
Polimorfismo Genético
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Enzymes); 0 (Pharmaceutical Preparations); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170819
[St] Status:MEDLINE
[do] DOI:10.1080/17460441.2017.1367280


  10 / 8052 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28818579
[Au] Autor:Sharma RP; Schuhmacher M; Kumar V
[Ad] Endereço:Center of Environmental Food and Toxicological Technology (TecnATox), Departament d'Enginyeria Química, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain.
[Ti] Título:Developing integrated PBPK/PD coupled mechanistic pathway model (miRNA-BDNF): An approach towards system toxicology.
[So] Source:Toxicol Lett;280:79-91, 2017 Oct 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Integration of a dynamic signal transduction pathway into the tissue dosimetry model is a major advancement in the area of computational toxicology. This paper illustrates the ways to incorporate the use of existing system biological model in the field of toxicology via its coupling to the Physiological based Pharmacokinetics and Pharmacodynamics (PBPK/PD) model. This expansion framework of integrated PBPK/PD coupled mechanistic system pathway model can be called as system toxicology that describes the kinetics of both - the chemicals and - biomolecules, help us to understand the dynamic and steady-state behaviors of molecular pathways under perturbed condition. The objective of this article is to illustrate a system toxicology based approach by developing an integrated PBPK/PD coupled miRNA-BDNF pathway model and to demonstrate its application by taking a case study of the PFOS mediated neurotoxicity. System dynamic involves miRNA-mediated BDNF regulation, which plays an important role in the control of neuronal cell proliferation, differentiation, and survivability.
[Mh] Termos MeSH primário: Fator Neurotrófico Derivado do Encéfalo/metabolismo
Regulação da Expressão Gênica/fisiologia
MicroRNAs/metabolismo
Modelos Biológicos
Farmacocinética
RNA Mensageiro/metabolismo
[Mh] Termos MeSH secundário: Ácidos Alcanossulfônicos/farmacocinética
Fator Neurotrófico Derivado do Encéfalo/genética
Simulação por Computador
Fluorcarbonetos/farmacocinética
Seres Humanos
MicroRNAs/genética
RNA Mensageiro/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkanesulfonic Acids); 0 (Brain-Derived Neurotrophic Factor); 0 (Fluorocarbons); 0 (MicroRNAs); 0 (RNA, Messenger); 9H2MAI21CL (perfluorooctane sulfonic acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170819
[St] Status:MEDLINE



página 1 de 806 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde